Broader coverage than Zepbound because diabetes is a more covered indication
Of those receiving the Zepbound injection, 8 of 10 people (80%) experienced peak levels on Day 2 of the Study and subsequently experienced declining levels, whereas of those receiving the DehydraTECH-tirzepatide, 4 of 8 people (50%) experienced their peak levels on the final day of the Study, indicating that their levels were still rising at the conclusion of the Study
4 Need for long-term therapy Obesity is a chronic disease
9597 Peripheral activation of GLP-1 receptors triggers a cascade of metabolic effects, including slowed gastric emptying, reduced appetite, lower hepatic glucose production, enhanced insulin synthesis and sensitivity, and improved cardiovascular functions such as vasodilation and cardiac output
Published in 1982 the additional sequence appeared to code for a peptide that resembled GIP which in the meantime had been shown to boost glucagon (Lund, Goodman, Dee, Habener
5 This is in contrast to the typical call for most accidental overdoses involving children